The latest price target for Corbus Pharmaceuticals (NASDAQ:CRBP) was reported by RBC Capital on May 7, 2025. The analyst firm set a price target for $58.00 expecting CRBP to rise to within 12 months (a possible 685.91% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Corbus Pharmaceuticals (NASDAQ:CRBP) was provided by RBC Capital, and Corbus Pharmaceuticals maintained their outperform rating.

The last upgrade for Corbus Pharmaceuticals Holdings Inc happened on March 6, 2024 when Jefferies raised their price target to $46. Jefferies previously had a hold for Corbus Pharmaceuticals Holdings Inc.

There is no last downgrade for Corbus Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.

While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a maintained with a price target of $65.00 to $58.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $7.38, which is out of the analyst’s predicted range.